This "fall" start of human trial news is a blessing, if true. Who wants your birthday and Christmas falling on the same day. Sure, you may get some "double presents," but most people will probably give you one present as a gift for both occasions. What's important here, and what is driving the last 8-10 weeks of an uptreding stock price is the imminent up-listing catalyst. Up-listing is THE catalyst. Once we uplist, a whole new bunch of holders will become a part of the Invivo story, which will perfectly transition into the next major catalyst, human testing beginning.
Before getting FDA approval to run a trial protocols must be included within the application. In fact, protocols are a good part of the reason this trial has been delayed for over two years now (CEO originally was talking about clinical trial beginning in 2010). It appears they got approval, tried to implement the protocols, could not, and have to go back to the drawing board after spending two years trying to work them out with the FDA. That is not a good thing because this is appearing more like DSCO than LPTN in which delays were just a minor hiccup.
It is not like NVIV would ever disclose the basis for the delays which is why you should be careful at this point.
I'm sorry but the FDA doesn't work that way I'm afraid. The hard work is long over (hence the 2 year delay), and I assure you, this is NOT going back to the drawing board, as much as you want to create the idea that it is. Nice try though.